Efficacy and Safety of Low-Dose Versus Standard-Dose Alteplase to Treat High-Risk Pulmonary Embolism.
Clinical takeaway This small observational cohort found no statistically significant difference in haemodynamic stability or mortality between dosing groups. The shorter ventilation duration is hypothesis-generating rather than evidence of a causal benefit.